Quantify any protein, in any sample, with any modification, without antibodies
Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
September 24-27, 2023 Norfolk, VA Join the Inotiv team of experts at the 76th Tobacco Science Research Conference held September 24-27 in Norfolk, VA: Looking Forward – The Challeng...
September 26, 2023 San Francisco, CA hubXchange’s Immuno-Oncology Xchange West Coast 2023 will bring together executives from pharma and biotech to address and find solutions to the k...
Inotiv scientists are co-authors on a paper in Regulatory Toxicology and Pharmacology journal, exploring the potential reproductive toxicity of gardenia blue natural food coloring. Natural food colorants ar...
August 29, 2023 WEST LAFAYETTE, Ind., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a lead...
August 24, 2023 WEST LAFAYETTE, Ind., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a lead...
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
In Vivo Services
Histology
Pathology
DMPK
Consulting
Research Models
Research Model Services
Teklad Diet and Bedding
